Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Fatty Liver Treatment Market Size Changed, over the years?

The market size of treatments for fatty liver conditions has experienced robust growth in the previous years. It is projected to increase from a size of $23.73 billion in 2024 to reach $25.12 billion the following year. This growth represents a compound annual growth rate (CAGR) of 5.8%. Factors such as the widespread occurrence of obesity, inactive lifestyles, poor dietary habits, limited treatment methods and generalised awareness initiatives have all contributed to the noted upward growth trend in the past.

How Much Will the Fatty Liver Treatment Market Be Worth in 2029?

The market for fatty liver treatment is projected to experience significant expansion in the coming years, growing to a value of $33.07 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 7.1%. The predicted growth during this forecast period can be linked to factors such as higher incidence of the disease, increased healthcare spending, the spread of diabetes and metabolic syndrome, as well as innovative therapeutics. Additionally, the forecast period is expected to witness trends such as precision medicine strategies, lifestyle alteration programs, targeted treatments for Nash, non-invasive examination tools, and technological advancements.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12581&type=smp

Which is the Largest Company in the Fatty Liver Treatment Market?

Major companies operating in the fatty liver treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, GlaxoSmithkline plc, Mitsubishi Chemical Holdings, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Eisai Co. Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, GW Pharmaceuticals Limited, Retrophin Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., AbbKine Scientific Co. Ltd., Daewoong Co. Ltd., Madrigal Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Limited, Genfit, NGM Biopharmaceuticals Inc., Cardax Inc., Conatus Pharmaceuticals Inc., Limerick Biopharma Inc.

What Are the Main Market Drivers in the Fatty Liver Treatment Industry?

The fatty liver treatment market is likely to expand as a result of a rise in alcohol consumption. Drinking alcohol, which is a psychoactive substance that depresses the central nervous system, amplifies the risk of enhanced fatty liver disease and could potentially cause more serious conditions such as alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. As per the HRB National Drugs Library, a governmental organization based in Ireland, the consumption of alcohol in Scotland spiked to 10.2 liters of pure alcohol per capita for individuals aged over 15 in 2022, marking a 7.6% growth compared to 2021 and illustrating a worrisome increase in alcohol consumption despite consistent public health campaigns to curtail it. Thus, the surge in alcohol consumption is fuelling the growth of the fatty liver treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12581&type=smp

How Is the Fatty Liver Treatment Market Segments Structured?

The fatty liver treatment market covered in this report is segmented –

1) By Treatment Type: Anti-Rejection Drugs Or Immunosuppressants, Chemotherapy Drugs, Targeted Therapy, Vaccines, Anti-Viral Drugs

2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases

3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users

Subsegments:

1) By Anti-Rejection Drugs Or Immunosuppressants: Corticosteroids, Calcineurin Inhibitors, mTOR Inhibitors

2) By Chemotherapy Drugs: Conventional Chemotherapy Agents, Novel Chemotherapeutics Under Investigation

3) By Targeted Therapy: Small Molecule Inhibitors, Monoclonal Antibodies

4) By Vaccines: Therapeutic Vaccines, Preventive Vaccines

5) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs), Nucleos(t)ide Analogs

What Strategic Trends Are Transforming the Fatty Liver Treatment Market?

The fatty liver treatment market is increasingly observing the emergence of product innovation as a pivotal trend. Noteworthy companies in the market are cropping up with innovative solutions to consolidate their market footing. Akero Therapeutics, a biotech firm based in the US, disclosed encouraging Phase II results of efruxifermin in March 2023. This product is devised for treating non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that have been diagnosed non-invasively. Efruxifermin, a distinctive Fc-FGF21 fusion protein, imitates the bioactivity of fibroblast growth factor 21 (FGF21) that controls an array of cellular procedures and metabolic pathways.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Which Global Regions Offer the Highest Growth in the Fatty Liver Treatment Market?

North America was the largest region in the fatty liver treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12581

This Report Delivers Insight On:

1. How big is the fatty liver treatment market, and how is it changing globally?

2. Who are the major companies in the fatty liver treatment market, and how are they performing?

3. What are the key opportunities and risks in the fatty liver treatment market right now?

4. Which products or customer segments are growing the most in the fatty liver treatment market?

5. What factors are helping or slowing down the growth of the fatty liver treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model